Grant: Collaborative Research and Development Grants
Queen's University
$59,663.00
Synthesis of deuterium labelled pharmaceutical compounds with improved efficacy
EF 2019-20
Résumé
Organic synthesis involves making carbon-based complex molecules from simple ones, just as Lego blocks areclicked together to form large educational and playful structures. Methods for synthesis have advanced andmultiplied so that today we can make complicated molecules, some of which provide medicines andagricultural agents for the benefit of humankind. Today, a very active area, especially in industrial laboratories,is the synthesis of deuterium (D)-containing pharmaceuticals. The replacement of hydrogen (H) of a given drugwith D results in modification/retardation of metabolic fate and alters the therapeutic profile while retaining thebiological potency of the non-D molecules. Thus, the development of D-analogues of currently approvedpharmaceuticals could lead to a positive impact on the safety, efficacy and tolerability of these drugs,addressing important but unmet medical needs. This proposal aims to address these needs by the synthesis of aseries of D-analogues of currently significant marketed drugs. The proposed research is based on ourconsiderable experience in the discovery and development of directed ortho metalation (DoM) and relatedtechnologies for the preparation of aromatic and heteroaromatic molecules. These classes of molecules are themainstay of pharmaceuticals (80% of modern drugs) and are used by industry (e.g. Monsanto, Pfizer, BMS,Merck) for the multi-kg synthesis of marketed pharmaceuticals. We also have a strong knowledge base on thepreparation of D-molecules since this is the backbone reaction of our DoM synthetic strategies. Based on thisbackground and experience, our goals are: a) to incorporate D into commercially available drugs, establishingsynthetic feasibility; b) to develop fundamentally new synthetic steps for introduction of D at early or lateintermediate stages; and c) to develop new routes that truncate known procedures. We anticipate that theresearch will provide Sussex Research an advantage over non-Canadian competitors, and thereby will have apositive impact on the Canadian economy as well as train highly qualified scientists for the Canadian labourmarket.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
523925-2018
Name nom
Snieckus, Victor
Department département
Chemistry
Organization id
29
Institution établissement
Queen's University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2018
Award amount
59663
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1100
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Health, education and social services
Area of application fr
Santé publique, éducation et services sociaux
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Installment
inst:2 - 2
Partie
2
Nb partie
2
Application title
Synthesis of deuterium labelled pharmaceutical compounds with improved efficacy
Keyword
NSERC
Application summary
Organic synthesis involves making carbon-based complex molecules from simple ones, just as Lego blocks areclicked together to form large educational and playful structures. Methods for synthesis have advanced andmultiplied so that today we can make complicated molecules, some of which provide medicines andagricultural agents for the benefit of humankind. Today, a very active area, especially in industrial laboratories,is the synthesis of deuterium (D)-containing pharmaceuticals. The replacement of hydrogen (H) of a given drugwith D results in modification/retardation of metabolic fate and alters the therapeutic profile while retaining thebiological potency of the non-D molecules. Thus, the development of D-analogues of currently approvedpharmaceuticals could lead to a positive impact on the safety, efficacy and tolerability of these drugs,addressing important but unmet medical needs. This proposal aims to address these needs by the synthesis of aseries of D-analogues of currently significant marketed drugs. The proposed research is based on ourconsiderable experience in the discovery and development of directed ortho metalation (DoM) and relatedtechnologies for the preparation of aromatic and heteroaromatic molecules. These classes of molecules are themainstay of pharmaceuticals (80% of modern drugs) and are used by industry (e.g. Monsanto, Pfizer, BMS,Merck) for the multi-kg synthesis of marketed pharmaceuticals. We also have a strong knowledge base on thepreparation of D-molecules since this is the backbone reaction of our DoM synthetic strategies. Based on thisbackground and experience, our goals are: a) to incorporate D into commercially available drugs, establishingsynthetic feasibility; b) to develop fundamentally new synthetic steps for introduction of D at early or lateintermediate stages; and c) to develop new routes that truncate known procedures. We anticipate that theresearch will provide Sussex Research an advantage over non-Canadian competitors, and thereby will have apositive impact on the Canadian economy as well as train highly qualified scientists for the Canadian labourmarket.